A Phase III Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer

• Status: Not yet recruiting
• Trial end date: 2027-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety of SKB264 in patients with unresectable locally advanced, recurrent, or metastatic HR+/HER2- breast cancer.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
• Treatments: Capecitabine; Gemcitabine; Vinorelbine

Criteria

Inclusion Criteria:

• Males or females aged ≥ 18 to ≤ 75 years at the time of signing the ICF;

• Histologically and/or cytologically confirmed HR+/HER2- breast cancer based on pathology reports on recent biopsy specimens or other pathological samples;

• Patients who had failed at least one line of systemic chemotherapy in unresectable locally advanced, recurrent, or metastatic stage;

• Patients with at least one measurable lesion per RECIST 1.1 criteria; those with only skin or bone lesions cannot be included;

• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1;

• Expected survival ≥ 12 weeks;

• Adequate organ and bone marrow function;

• Patients who are eligible for a chemotherapy regimen in the control group;

• Female patients of childbearing potential and male patients with partners of childbearing potential who use effective medical contraception from the time of signing the informed consent form until 6 months after the last dose;

• Patients who voluntarily participate in the study and sign the ICF, and able to comply with the visit and related procedures stipulated in the plan.

Exclusion Criteria:

• Patients with a history of central nervous system (CNS) metastases or current CNS metastases；

• Patients with other malignancies (except cured basal or squamous cell skin cancer or carcinoma in situ of the cervix) within 3 years prior to the first dose;

• Patients with any cardio cerebral Vascular disease or cardio cerebral vascular risk factors may affect investigational treatment;

• Uncontrollable systemic diseases assessed by the investigator;

• History of (noninfectious) interstitial lung disease (ILD)/noninfectious neumonitis requiring steroid therapy and current ILD/noninfectious pneumonitis, or ILD/noninfectious pneumonitis at screening that cannot be excluded by imaging;

• Clinically serious lung injuries caused by lung diseases;

• Patients with active chronic Inflammatory bowel disease, gastrointestinal obstruction, severe ulcer, gastrointestinal perforation, abdominal abscess or acute gastrointestinal bleeding;

• Toxicities from prior anti-tumor therapy not recovering to ≤ Grade 1;

• Active hepatitis B or hepatitis C;

• Human immunodeficiency virus (HIV) antibody test positive or a history of acquired immunodeficiency syndrome (AIDS), known active syphilis infection;

• Known allergy or hypersensitivity to SKB264, or the excipients of SKB264;

• Prior TROP2 targeted therapy, prior topoisomerase I inhibitor therapy, including antibody-drugconjugate(ADC) therapy;

• Patients who received major surgeries 4 weeks prior to the first dose of study treatment or planned to receive major surgeries during the study ;

• Patients with concomitant infections requiring systemic antibiotic therapy within 2 week prior to the first dose of study treatment;

• Patients who have received live vaccines within 30 days prior to the first dose, or are scheduled to receive live vaccines during the study;

• Pregnant or lactating women.